We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Salarius Pharmaceuticals is a clinical-stage biotechnology company focused on developing effective cancer treatments for patients who need them most. Salarius was formed in 2011 after licensing the technology related to their lead compound from the University of Utah. Following formation, Salarius focused on identifying and progressing their lead therapeutic candidate to IND approval. As part of this process, Salarius was able to generate impressive preclinical data that was instrumental in being selected to receive an $18.7M grant from the Cancer Prevention & Research Institute of Texas (CPRIT). Salarius received IND activation from the FDA in March 2018. In 3Q2018 Salarius initiated a Phase 1 clinical trial in Ewing sarcoma and will be opening an additional Phase 1 trial in Advanced Solid Tumors in 1H2019.